Pembrolizumab consists of a humanized mouse- derived PD-1 (programmed cell death protein 1) antibody that interrupt programmed death-ligand 1 (PD-L1) ligation promoting tumor cells apoptosis. The gene discussed is PDCD1; the disease is neoplasm.